The discussion centered on optimizing leukemia treatment strategies through the combination of immunotherapies and chemotherapy. The concern of CNS relapse…
This in-depth discussion among experts explores various facets of leukemia management. The conversation spans topics including challenges in clonotypable patients,…
Medical experts engaged in a discussion about advancing pediatric acute myeloid leukemia (AML) treatment strategies. Venetoclax, a promising drug, was…
Navigating the ever-evolving landscape of leukemia treatment has become an intricate endeavor, with recent clinical trials offering intriguing insights and…
The conversation focuses on AML treatments, including arsenic and another frontline approach. Preventing relapses through non-toxic drugs like masitinib is…
In this discussion, the focus is on optimizing Acute Myeloid Leukemia (AML) treatment. The idea of reducing drug doses upon…
Leading experts engage in a comprehensive discussion on the intricate landscape of long-term remission and resistance patterns in transplanted acute…
Ryan Fitzpatrick, CEO, MD Education In opening the Focus Meeting 2023, Ryan Fitzpatrick, CEO, expresses gratitude to attendees and collaborators…
The discussion revolves around complex topics related to acute myeloid leukemia (AML), including its groups, molecular markers, patient eligibility for…
In the ever-evolving landscape of medical science, melanoma and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)…
Joseph D. Khoury, MD is the Stokes-Shackleford Professor and Chair, Department of Pathology and Microbiology, University of Nebraska Medical Center.…
Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute Harry Erba, MD, a respected Duke…
Amir Fathi, MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital. Amir Fathi MD, an esteemed professional…
Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University…
Courtney D. DiNardo, MD, MSCE Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson…
Eytan M. Stein, MD – Leukemia & Early Drug Development Specialist – David H. Koch Center for Cancer Care at Memorial…
Naval G. Daver, MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval G.…
Brian Andrew Jonas, MD, Ph.D. Associate Professor of Medicine (Clin X) – UC Davis Comprehensive Cancer Center Brian Jonas MD, Ph.D.…
Marina Konopleva, M.D., Ph.D. Professor, Department of Oncology (Medical Oncology) and Department of Molecular Pharmacology Albert Einstein College of Medicine Jack and…
Hi Nkem – I just wanted to reach out and introduce myself. I’m Allen Wilbanks here at OncologyTube. It seems…
Hi Maria, I’m Allen Wilbanks and I’m taking over all of Scott Nasiff’s accounts here at OncologyTube and I thought…
Hi Frances, Hope you are well. You had reached out to OncologyTube on July 4th and I sent you some…
Breast cancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide,…
Hi Dina, just wanted to say and let you know that we just registered for SABCS 2023 so we will…
Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Marlise R. Luskin, MD, MSCE is a physician in Dana-Farber’s Adult Leukemia program. Meet Marlise Luskin, MD, MSCE, an esteemed…
Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD, MSCE…
Shira N. Dinner, MD. Associate Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Sherra Diner, MD, an esteemed associate…
Hagop M. Kantarjian, MD. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,…
Tapan M. Kadia, MD. Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX Tapan Kadia,…
Bijal Shah, MD, MS Hematology/Oncology H. Lee Moffic Cancer Center In the video, Bijal Shah, MD, MS discusses the significance…
Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) Meet Aaron…
Anjali Advani, MD – Hematology and Medical Oncology – Cleveland Clinic Meet Anjali Ifani, MD the esteemed Director of the…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX This conference…
Esophageal adenocarcinoma is a subtype of cancer that arises from the glandular cells in the esophagus, the muscular tube responsible…
Dr. Kevin Harrington, Phd of the Royal Marsden Hospital, The Institute of Cancer Research, London, is the author of this…
Chronic Lymphocytic Leukemia (CLL), a type of cancer that begins in the bone marrow and invades the blood, is one…
Ann M. Gillenwater, MD – MD Anderson, Department of Head and Neck Surgery, Division of Surgery presents the First Safety…
Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you…
In this video, Dr. Samuel Klempner, MD summarizes the phase 3 STAR-221 clinical trial investigating a novel treatment for advanced…
Anju Replacement
Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the…
Sarbajit Mukherjee, MD, MS, Assistant Professor, Roswell Park Comprehensive Cancer Center conducted a study to investigate the efficacy of a…
Tune in to the 2022 Targeted Therapies Forum to explore the critical role of nutrition in cancer treatment, discussed by…
Navigating the world of cancer care requires ample support for patients and their caregivers. In this enlightening video, Dr. Aakash…
Opening up to loved ones about a cancer diagnosis is a deeply personal and often challenging experience. In this thought-provoking…
Understanding when to adjust cancer treatment is paramount in patient care. In this crucial session, Drs. Desai, Khalil, and Luo…
The landscape of treating KRAS+ NSCLC (Non-Small Cell Lung Cancer) is evolving, and understanding how to approach patient care after…
Handling the stress associated with cancer scans is a vital aspect of care for both patients and healthcare professionals. In…
Drs. Khalil, Luo, Desai, and Preeshagul in this insightful video from the 2022 Targeted Therapies Forum as they discuss effective…
Dr. Maya Khalil dives into the intricacies of RET+ NSCLC treatments in our 2022 Targeted Therapies Forum. Gain insights as…
In the esteemed 2022 Targeted Therapies Forum, Dr. Jia Luo, renowned Medical Oncologist from Dana-Farber Cancer Institute and respected Instructor…
In an inspiring session from the 2022 Targeted Therapies Forum, Terri Conneran, lung cancer survivor and the visionary Founder of…
Dive deep into the world of RET+ NSCLC treatment options with Dr. Maya Khalil, an esteemed Hematology-Oncologist from the Kirklin…
Join Dr. Maya Khalil, renowned Hematology-Oncologist from Kirklin Clinic of UAB Hospital and Assistant Professor at the University of Alabama…
Delve deep into the world of RET+ NSCLC with Dr. Maya Khalil, a distinguished Hematology-Oncologist from the Kirklin Clinic of…
Unveiling the latest insights on KRAS+ NSCLC, join Dr. Jia Luo, an esteemed Medical Oncologist at Dana-Farber Cancer Institute and…
Decoding the complexities of biopsies for KRAS+ NSCLC, join Dr. Jia Luo, a prominent Medical Oncologist at Dana-Farber Cancer Institute…
Demystifying treatment timelines for KRAS+ NSCLC, the 2022 Targeted Therapies Forum presents Dr. Jia Luo, an esteemed Medical Oncologist from…
Explore the landscape of KRAS+ NSCLC treatment in the 2022 Targeted Therapies Forum with Dr. Jia Luo, a distinguished Medical…
Dive deep into the world of Next-Generation Sequencing (NGS) tests in our 2022 Targeted Therapies Forum’s breakout session. Esteemed oncologists…
Welcome to the 2022 Targeted Therapies Forum’s breakout session, where renowned oncologist Dr. Dagogo-Jack delves into the nuances of BRAF…
Delving into the intricate landscape of NSCLC management, the 2022 Targeted Therapies Forum presents a dedicated breakout session on ‘First…
In a specialized breakout session from the 2022 Targeted Therapies Forum, Dr. Nagashree Seetharamu delves deep into the world of…
Dive into the intricacies of NTRK mutations in non-small cell lung cancer with Dr. Nagashree Seetharamu in this enlightening session…
Ever wondered about the nuances of NTRK mutations in oncology? Join Dr. Nagashree Seetharamu in this enlightening session from the…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Ibiayi Dagogo-Jack examines whether BRAF/MEK combination treatment works in all…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo and Jeffrey Thompson answer a question regarding hormonal…
Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss Crizotinib as adjuvant treatment for ROS1+…
Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss when to use targeted therapy in…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo answers a question regarding developing a second mutation…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson examines results from several trials for HER2+ NSCLC…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson looks at HER2+ NSCLC closely, including treatment options.…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson discusses the evolving field of NSCLC treatment, and…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo examines the use of chemotherapy and immunotherapy in…
Dive into the ever-evolving world of ROS1+ treatment options with Dr. Alejandro Calvo. In this specialized session from the 2022…
Unravel the complexities of ROS1+ NSCLC treatment with Dr. Alejandro Calvo. In this illuminating segment from the 2022 Targeted Therapies…
Dive deep into ROS1+ NSCLC with Dr. Alejandro Calvo. In this captivating segment from the 2022 Targeted Therapies Forum, gain…
Experience the transformation of lung cancer treatment over the years with Dr. Alejandro Calvo. This 2022 Targeted Therapies Forum session…
Considering traveling for a clinical trial? Before you pack your bags, get expert insights from Dr. Angel Qin in this…
Disease progression in cancer treatments can be complex, especially when it comes to commonly used medications like Lorlatinib or Osimertinib.…
Uncommon mutations present unique challenges in cancer treatments, especially when it comes to EGFR mutations. In the 2022 Targeted Therapies…
As cancer treatment progresses, managing side effects becomes paramount. In this insightful session from the 2022 Targeted Therapies Forum, Drs.…
Dive deep into the world of EGFR TKIs with Dr. Millie Das and Angel Qin in this enlightening session from…
Explore the frontier of ALK+ NSCLC treatments in this in-depth session from the 2022 Targeted Therapies Forum, led by the…
Addressing the challenges of ALK TKIs, this insightful session from the 2022 Targeted Therapies Forum is brought to you by…
Dive into the dynamic world of ALK+ NSCLC treatment with Dr. Millie Das, a prominent figure in oncology, as she…
Understanding ALK+ NSCLC? Dive into this illuminating session as Dr. Millie Das, a renowned oncologist, breaks down what ‘ALK+’ signifies…
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses the use of Patritumab Deruxtecan for EGFR+ NSCLC. We thank…
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the…
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses next steps if Osimertinib stops working. We thank our sponsors…
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin examines the various TKIs for EGFR+ NSCLC, and their side effects.…
Targeted Therapies Forum 2022, Breakout Session: In this video Dr. Angel Qin explains what EGFR+ lung cancer is. We thank…
Targeted Therapies Forum 2022: In this video Drs. Desai, Kim, and Florez discuss whether side effects of TKIs decrease over…
Targeted Therapies Forum 2022: In this video, Drs. Preeshagul, Florez, Hirsch, and Kim discuss what it means when a patient…
Targeted Therapies Forum 2022: In this video, Dr. Chul Kim discusses how to treat the rare percentage of patients with…
Targeted Therapies Forum 2022: In this video Dr. Narjust Florez addresses the complicated question of progression for a patient with…
Targeted Therapies Forum 2022: In this video Dr. Aakash Desai presents Dr. Chul Kim response to a patient who is…
Targeted Therapies Forum 2022: In this video Dr. Isabel Preeshagul presents Dr. Fred R. Hirsch response to a patient who…
Targeted Therapies Forum 2022: In this video Drs. Isabel Preeshagul and Narjust Florez, discuss treatment of a patient diagnosed with…
Targeted Therapies Forum 2022: In this video Drs. Aakash Desai and Narjust Florez, discuss how she approaches oligoprogression with mutations…
Targeted Therapies Forum 2022: In this video Drs. Isabel Preeshagul and Chul Kim, discuss if side effect symptoms mean a…
Targeted Therapies Forum 2022: Dr. Aakash Desai, Hematology/Oncology Fellow, Mayo Clinic, Rochester, MN, and Dr. Fred R Hirsch, Executive Director,…
Targeted Therapies Forum 2022: Dr. Aakash Desai, Hematology/Oncology Fellow, Mayo Clinic, Rochester, MN, and Dr. Fred R Hirsch, Executive Director,…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
Colorectal cancer is a growing concern, and its incidence among younger individuals, known as young-onset colorectal cancer (yoCRC), has been…
KEY TAKEAWAYS Bispecific antibodies, such as talquetamab, represent a transformative shift in cancer treatment, offering the potential to target two…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
For this year’s post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and…
KEY TAKEAWAYS: Ribociclib, a CDK4/6 inhibitor, is a promising drug in the treatment of early-stage and metastatic breast cancer, particularly…
Lung cancer screening has emerged as an essential tool in identifying the disease at its early stages, when it is…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
Clinical trials, as many are aware, often face numerous failures. Countless molecules are tested before finding a successful one. Anju,…
Gliomas are a complex group of brain and spinal cord tumors that start from glial cells, which are cells that…
BRAF V600E colon cancer is a subtype of colorectal cancer characterized by a specific genetic mutation known as BRAF V600E.…
TROPiCS-02 Trial: The TROPiCS-02 trial showcases the potential of Sacituzumab Govitecan, a Trop-2 directed antibody-drug conjugate, as a promising treatment…
Dr. Jack West, MD, an associate professor in medical oncology focused on thoracic oncology at the City of Hope Comprehensive…
Abemaciclib, a CDK4 & 6 inhibitor, has shown a sustained benefit in invasive disease-free survival in high-risk EBC, as seen…
Thromboembolism are highly prevalent and burdensome in patients with cancer. Risk for venous thromboembolism (VTE) varies widely across specific cancer…
Chronic Lymphocytic Leukemia (CLL) is a serious condition, and the current standard treatment involves a combination of Ibrutinib and Obinutuzumab…
Welcome to our in-depth exploration of a topic of big importance in the field of oncology: Metastatic Castration-Resistant Prostate Cancer…
Prithvi Bose, an associate professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, focuses on…
Today we talk about a topic that has been stirring considerable interest in the oncology field, promising an innovative approach…
Refractory multiple myeloma remains a significant challenge in the field of oncology, necessitating innovative therapeutic strategies. Mezigdomide, a novel oral…
Pembrolizumab plus Lenvatinib, individually known for their robust anti-cancer mechanisms, when combined, show significant promise in treating advanced renal cell…
In ASCO 2023, the highly anticipated results of the Adora study were unveiled, providing valuable insights into the efficacy and impact…
… Metastatic colorectal cancer (mCRC) continues to be a significant health challenge worldwide. Despite advancements in treatment methods, the prognosis…
Vorasidenib (AG-881) is a promising targeted therapy for gliomas with IDH1 or IDH2 mutations. This novel approach could potentially revolutionize…
FOTIVDA is Aveo’s marketed product for treating advanced renal cell carcinoma, primarily used as a later line agent in the…
Sotorasib, as demonstrated by the CodeBreaK 200 study, is a promising treatment for patients with KRAS G12C-mutated advanced NSCLC, with…
Vorasidenib, an oral, brain-penetrant, dual inhibitor of mutant IDH1/2 enzymes, shows promise in treating grade 2 gliomas. The INDIGO trial,…
… The battle against cancer has led to a myriad of innovations in oncology, with each new breakthrough providing a…
Infigratinib, an FGFR1-3 inhibitor, has shown promise as an adjuvant therapy for invasive urothelial carcinoma. The FDA has approved infigratinib…
Constantinos Savva, MD, M.Sc., PGDip, MRCP, SCE, from the University of Southampton conducted a study on the effects of metformin,…
Michael Chuong, MD, from Baptist Health has conducted a Phase 2 trial on the use of ablative MRI-guided stereotactic body…
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in…
Cody Peer, PhD, from the National Institutes of Health, is conducting a randomized research study comparing the dosing intervals of…
Manojkumar Bupathi, MD, from the Rocky Mountain Cancer Centers, conducted a study to evaluate the effectiveness of sacituzumab govitecan (SG)…
KEYNOTE-716 trial brings to light the impressive efficacy of pembrolizumab as an adjuvant therapy for stage IIB or IIC melanoma.…
Anthony Stein, MD, from the City of Hope, has conducted a first-in-human study to evaluate the safety and efficacy of…
The Impact of ASCO 2022 on Oncology In the ever-evolving field of oncology, ASCO 2022 stands out as a landmark…
Majid Jaberi-Douraki, PhD from Kansas State University, and Shahzad Raza, MD from the Cleveland Clinic, conducted a study to evaluate…
Manojkumar Bupathi, MD, MS, from Rocky Mountain Cancer Centers, conducted a safety analysis on cohort 1 of the TROPHY-U-01 phase…
Ismael Rodriguez Rivera, MD, Medical Oncologist and Clinical Investigator from NEXT Oncology, has conducted a groundbreaking study on a novel…
Advanced Urothelial carcinoma, primarily affecting the urinary system, is a typically aggressive cancer with limited treatment options. Pembrolizumab, an immunotherapy…
Erika Hamilton, MD, a preeminent expert from the Sarah Cannon Research Institute, has recently conducted a study evaluating the efficacy…
Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle…
Roy Herbst, MD, PhD, from the Yale Cancer Center and Yale School of Medicine, presented a groundbreaking abstract at the…
Non-Small Cell Lung Cancer (NSCLC) is a complex and aggressive form of lung cancer, but developments in treatments and therapies…
Brexucabtagene autoleucel (Tecartus) is a ground-breaking CAR T-cell therapy for the treatment of relapsed or refractory mantle cell lymphoma. The…
Caicun Zhou, MD, PhD – Tongji University Shanghai Pulmonary Hospital Sunvozertinib established itself as the leading targeted therapy for NSCLC…
Ian Krop, MD, PhD – Yale University This study conducted an age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients…
Ian B. Walters, MD – Portage Biotech Inc The IMPORT-201 study investigates the use of IMM60, a novel iNKT agonist,…
Jonathan David Tward ,MD, PHD, FASTRO – University of Utah A study using the Prolaris test shows that it can…
Nicholas Robert, MD – Chief Medical Officer of Ontada Nicholas J. Robert, the chief medical officer at Ontada, is responsible…
Majid Jaberi-Douraki, PhD -Kansas State University and Shahzad Raza, MD – Cleveland Clinic This study analyzed data from the FDA…
Scott T Tagawa, MD, MS, FASCO, FACP – Weill Cornell This study explores the use of a combination therapy, involving…
Qing Zhou, MD – Guangdong Lung Cancer Institute Preliminary data from a phase I/II study of KL590586, a next-generation selective…
Ari Rosenberg, MD – University of Chicago The DEPEND trial investigated the use of neoadjuvant nivolumab, paclitaxel, and carboplatin followed…
by: Niels Van de Donk, MD, Amsterdam UMC Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, continues to show…
Glenn Hanna, MD – Dana-Farber The combination of BCA101 and pembrolizumab as first-line therapy in patients with recurrent, metastatic head…
Omid Hamid, MD – The Angeles Clinic This phase 1/2 study evaluated the combination therapy of retifanlimab, INCAGN02385 (Anti–LAG-3), and…
Laure-Anne Teuwen, MD, PhD from Antwerp University Hospital, and Joanna Young, DO, FACP from Blue Ridge Cancer Care examined the…
Patrizia Giannatempo, MD, from the Fondazione IRCCS Istituto Nazionale dei Tumori, has conducted extensive research on the impact of histology…
Prof. Arun Azad, MBBS, PhD from the Peter MacCallum Cancer Centre, has recently conducted a Phase 3 clinical trial called…
Monique Hartley-Brown, MD, MMSc, from Dana-Farber Cancer Institute, conducted a significant clinical study called “SUCCESSOR-2” that focused on the treatment…
Karan Dixit, MD, from Northwestern Medicine, delivered a compelling presentation during the Plenary Session at the recent conference on glioma…
Rona Yaeger, MD, an eminent oncologist from Memorial Sloan Kettering Cancer Center, is currently involved in a significant clinical trial…
Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, has conducted a randomized, phase 3 study called LUNAR,…
Petros Grivas, MD, PhD, an expert in urothelial carcinoma (UC) research at the University of Washington, has made significant contributions…
Sara Tolaney, MD, a renowned researcher from the Dana-Farber Cancer Institute, has recently conducted a groundbreaking study that has been…
Jason Luke, MD, FACP, a renowned medical professional affiliated with the University of Pittsburgh Medical Center (UPMC), recently conducted a…
Swetha Kambhampati, MD from the City of Hope talks about the ASCO 2023 abstract about Mantle Cell Lymphoma Real-World Outcomes of…
The phase 3 FRESCO-2 study evaluated the efficacy and safety of fruquintinib, a novel targeted therapy, in patients with advanced…
Ferdinandos Skoulidis, MD, PhD, from the MD Anderson Cancer Center, presented the results of biomarker subgroup analyses from the phase…
J. Randolph Hecht, MD from UCLA Health is conducting a phase 3 clinical trial called STELLAR-303 to evaluate the efficacy…
Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of…
This is a deep dive into the groundbreaking NAPOLI-3 Trial, a study that has generated significant interest and discussion in…
Adam Brufsky, MD, PhD from the University of Pittsburgh discussed the higher risk of recurrence in certain breast cancer patients…
Omid Hamid, MD from The Angeles Clinic & Research Institute reports on the best Cutaneous Treatments from ASCO 2023 and…
Dr. Monica Niger, from Fondazione IRCCS Istituto Nazionale Tumori, provided a summary of the NALIRIFOX vs FOLFIRINOX vs gemcitabine plus…
Dr. Katherine Peters from Duke University Medical Center discussed the current treatments and their limitations for low-grade glioma patients with…
High-grade gliomas represent a significant burden in neuro-oncology, affecting thousands of individuals worldwide each year. Gliomas, a form of brain…
“Correction: The mPFS is not 34 months but 34%.” Carolina Schinke, MD from the UASM Health provided insights into the…
Introduction to Locally Advanced Breast Cancer Breast cancer is one of the most common types of cancer diagnosed in women…
Dr. Timothy Cloughesy, a prominent physician from UCLA Health, conducted the INDIGO clinical trial to evaluate the efficacy of Vorasidenib,…
Dr. Brian Hill, MD, PhD, from the Cleveland Clinic presented a study conducted through the Alliance and US cooperative groups,…
In this study, the researchers evaluated the use of standard of care (SOC) ciltacabtagene autoleucel in a patient population and…
Dr. David Peereboom from Cleveland Clinic conducted a phase one clinical trial called CRUX to investigate the efficacy and safety…
In this article, we dive deep into one of the potential advancement in the the evolving realm of medical science…
Head and neck cancer, collectively termed Head and Neck Cancer (HNC), is a group of biologically similar cancers that start…
Dr. Jessica Geiger from Cleveland Clinic presented an abstract at ASCO 2023 highlighting the potential of Enfortumab vedotin as a…
Dr. Atulya Khosla discussed the “Saved by the Scan” public service advertising program initiated by the American Lung Association (ALA)…
Dr. Suneel Kamath from the Cleveland Clinic – Young onset colorectal cancer (yoCRC) has been increasing over the past few…
by Hope Rugo, MD – UCSF Dr. Hope S. Rugo is a highly respected oncologist and professor of medicine specializing…
Locally advanced cervical cancer is a significant disease affecting young women, and the standard treatment options have not seen substantial…
Advanced Angiosarcoma (AS) is a rare and aggressive form of cancer that forms in the lining of blood vessels and…
In this enlightening interview, esteemed Oncologist Gary Schwartz, MD discusses the promising development and potential of Cabozantinib plus Nivolumab as…
ASCO 2023 Press Briefing June 6, 2024 with Julie Gralow, MD ASCO Chief Medical Officer
Join us in an insightful interview with renowned oncologist Dr. Emrullah Yilmaz, MD, PhD, as he discusses the potential of…
Squamous Cell Cancer, also known as squamous cell carcinoma (SCC), is an uncontrolled growth of abnormal cells arising in the…
The results of the CRUX study, which focused on the safety and feasibility of the JAK stat inhibitor Ruxolitinib in…
Dr. Javier Cortes discussed the PHERGain clinical study is a phase 2 trial focused on the potential deescalation of chemotherapy…
At the (ASCO) 2023 conference, Dr. Manmeet Singh Ahluwalla discussed, researchers presented the final trial report on a phase 1…
HPV Advances: Jill Meyer-Lippert, Dr. Jared Weiss, and Dr. Mary Cooley give an in-depth examination of HPV+ head and neck…
Brain metastases, or secondary brain tumors, occur when cancer cells spread from their original site to the brain. This devastating…
Decoding Recurrent Brain Metastases: The Power of 18F-Fluciclovine PET This discusses the challenges in detecting recurrent brain metastases and…
The medical field is abuzz with the exciting announcement of Novartis reporting positive topline results for the NATALEE trial (Phase…
iFrame is not supported! Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 Jack West…
Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at ASCO 2023 By Jack West, MD, associate professor…
Bladder Cancer Test: Does GALEAS Bladder aid in the early detection of bladder cancers? Prof. Bryan Dr. Ward Professor…
Bladder cancer test called “GALEAS Bladder” is a DNA-based diagnostic urine test designed to aid in the early detection of…
iFrame is not supported! Pembrolizumab combined with CG0070. How can this help patients with NMIBC? Roger Li Roger Li, MD…
The Roger Li, MD discussed the updated results from the CORE1 trial, which explored the combination of Cretostimogene Grenadorepvec (CG0070),…
iFrame is not supported! Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx By Tony Reid, MD, PhD,…
Molecule, RRx-001, has received fast track designation from the FDA. RRx-001 is a designer molecule with direct anti-inflammatory activity and…
Head and Neck Cancer: Discussion on Endocrine Oncology Research Innovations – Moffitt Moffitt Cancer CenterHost: Caitlin McMullen, MD, Member,…
Ovarian Cancer Treatment: What to Watch for In New and Novel Trials Shannon Westin MD By Shannon Westin, MD, MPH…
Breast Cancer Treatment: How is Biology’s Integration into the Clinic Transforming Healthcare? Hope Rugo By Hope Rugo, MD, FASCO, Professor,…
iFrame is not supported! Spatial Biology: Lunaphore’s COMET Portfolio Becomes the First Complete and Inclusive Solution Déborah Heintze By Déborah…
Lunaphore, COMET™ portfolio, spatial biology, end-to-end solution, universal solution, breakthrough technology, researchers, clinicians
A new CAR T-cell therapy strategy has shown significant effectiveness against small cell lung cancer, according to a preclinical study…
iFrame is not supported! CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD By Reiner Brentjens,…
iFrame is not supported! Breyanzi: CAR T-cell Therapy Gets Positive CHMP Opinion for R/R Large B-Cell Lymphoma Manali Kamdar MD…
Manali Kamdar, MD from University of Colorado Bristol Myers Squibb has received a positive opinion from the European Medicines Agency’s…
Ethnic Minorities: Empowering to Increase Colorectal Cancer Screening Through Community Outreach Kimlin Ashing PhD By Kimlin Tam Ashing, PhDProfessor, Department…
Cell Death: Drug Combo Restores Signaling Ability of Leading Treatment for Blood Cancer Christina Glytsou PhD By Christina Glytsou, PhDAssistant…
Gamma Delta: Two Phase 1 INDs Approved Announces Jeff Liter CEO Luminary Therapeutics By Jeff Liter, MBS, CEO of Luminary…
SOX9: Can this protein enable a molecular reversal that could lead to colorectal cancer? Nilay Sethi MD By Nilay Sethi,…
CAR T-cell: Advances in Adoptive Therapies for Targeting Heterogeneity in mCRPC Lupita Lopez By Lupita Lopez, BS Ph.D. candidate at…
Polatuzumab Vedotin: How can the POLARIX trial help us comprehend DLBCL? Connor Johnson MD By P. Connor Johnson, MD My…
Diabetes Cancer: Racial Disparities In Prevention An Epidemiological Perspective By Gaole Song By Gaole Song, DrPH From the City of…
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda By Professor Nagesh Kalakonda Thank you…
Focal Adhesion Kinase: Can Adding Fibroblasts and C-X-C Chemokine Help With Suppression? Arsen Osipov MD By Arsen Osipov, MD In…
Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area Anthony Tolcher MD By Anthony Tolcher, MD One of…
CD70: How Does ALLO-316 Eliminate or Destroy Malignancies in the TRAVERSE Trial? Samer Srour, MB ChB, MS By Samer Srour,…
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell…
Lisaftoclax (APG-2575): In CLL / SLL Treatment: Safety and Efficacy as Monotherapy or Combined with Acalabrutinib or Rituximab Matthew Davids…
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD By…
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids By Matthew…
Allogeneic Hematopoietic Cell Transplantation: How Can the ASAP Trial Help Relapsed or Refractory AML? Johannes Schetelig By Prof. Dr. med.…